Skip to main content
Ondine Biomedical Inc. logo

Ondine Biomedical Inc. — Investor Relations & Filings

Ticker · OBI ISIN · CA68234M2058 LEI · 9845005B69E07CGF4A56 TSXV Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2023-02-22 Regulatory Filings
Country CA Canada
Listing TSXV OBI

About Ondine Biomedical Inc.

https://ondinebio.com/

Ondine Biomedical Inc. is a life sciences company that develops and commercializes photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. The company's patented platform technology involves applying a photosensitive agent to a targeted area, followed by illumination with non-thermal laser light. This process creates an oxidative burst that rapidly destroys pathogens like bacteria, viruses, and fungi without inducing microbial resistance. Its lead product, Steriwave™, is a nasal decolonization therapy used to eradicate pathogens in the nasal cavity, primarily to reduce the risk of healthcare-associated infections (HAIs) such as post-operative surgical site infections. The company's product pipeline is exploring applications for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia.

Recent filings

Filing Released Lang Actions
Grant of Share Options
Regulatory Filings Classification · 98% confidence The document is an RNS announcement regarding the grant of share options to Non-executive Directors of Ondine Biomedical Inc. It includes the required FCA notifications for transactions by persons discharging managerial responsibilities (PDMR). While it involves directors, the primary nature of the filing is the disclosure of share-based compensation/transactions by PDMRs, which falls under the 'Director's Dealing' category.
2023-02-22 English
Ondine’s APDT reduces SARS-CoV-2 infectivity
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service). It announces the publication of a clinical study regarding the company's product, Steriwave. Since it does not fit into specific categories like financial results (ER/IR), governance (CGR), or corporate actions (SHA/POS), and serves as a general corporate announcement of a research milestone, it falls under the 'Regulatory Filings' (RNS) category.
2023-01-31 English
TR-1: Notification of major holdings
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by CRUX Asset Management regarding their interest in Ondine Biomedical Inc. This is a regulatory requirement for shareholders to disclose when their voting rights cross specific thresholds. This fits the definition of a Major Shareholding Notification (MRQ).
2023-01-17 English
New photodisinfection study published
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the London Stock Exchange's 'Reach' service, which is explicitly identified as a non-regulatory news service. It announces the publication of a scientific study regarding the company's photodisinfection technology. Since it does not fit into specific financial reporting categories like earnings, dividends, or governance, and serves as a general corporate announcement/press release, it falls under the 'Regulatory Filings' (RNS) category as the designated fallback for miscellaneous announcements.
2023-01-17 English
Second Price Monitoring Extn
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Second Price Monitoring Extension' for a security. It does not contain financial results, governance reports, or corporate actions, but rather a technical market trading update. As it is a regulatory announcement that does not fit into specific categories like M&A, dividends, or share issues, it falls under the RNS fallback category.
2023-01-13 English
Price Monitoring Extension
Regulatory Filings Classification · 100% confidence The document is a standard London Stock Exchange RNS (Regulatory News Service) notification regarding a 'Price Monitoring Extension' for a security. It is a technical market announcement generated by the exchange's trading system, not a corporate financial report or management disclosure. As it does not fit into specific categories like dividends, M&A, or director dealings, it falls under the general regulatory filing category.
2023-01-13 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.